Successful ABO incompatible heart transplantation after desensitization therapy in an older child

Pediatr Transplant. 2023 May;27(3):e14459. doi: 10.1111/petr.14459. Epub 2023 Jan 3.

Abstract

Background: ABO-incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers.

Methods: We report a case of an ABO-incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins.

Results: The anti-A titer at the time of HTx was 1:16 with post-transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post-HTx follow-up.

Conclusions: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better-matched allograft.

Keywords: ABO incompatibility; children; desensitization; heart transplantation.

Publication types

  • Case Reports

MeSH terms

  • ABO Blood-Group System
  • Adolescent
  • Blood Group Incompatibility
  • Child
  • Child, Preschool
  • Graft Rejection
  • Heart Transplantation*
  • Hemagglutinins*
  • Humans
  • Living Donors
  • Rituximab / therapeutic use

Substances

  • Hemagglutinins
  • Rituximab
  • ABO Blood-Group System